Multi-Center Study of Iron Overload: Survey Study (MCSIO)
- Conditions
- Sickle Cell DiseaseThalassemiaDiamond-Blackfan Anemia
- Registration Number
- NCT01913548
- Lead Sponsor
- UCSF Benioff Children's Hospital Oakland
- Brief Summary
The purpose of this study is to demonstrate that a sufficient number of iron-overloaded thalassemia (THAL), Sickle Cell Disease (SCD)and Diamond Blackfan Anemia (DBA) populations with similar duration of chronic transfusion, and age at start of transfusions would be available for a confirmatory study. The study will examine the hypothesis that a chronic inflammatory state in SCD leads to hepcidin- and cytokine-mediated iron withholding within the RES (reticuloendothelial system), lower plasma NTBI (non-transferrin bound iron) levels, less distribution of iron to the heart in SCD.
- Detailed Description
A detailed iron burden, transfusion and chelation history will be obtained from chart review or from participant recall.
Iron burden data will include: 1) documentation of liver iron, and 2) average annual ferritin values.
Transfusion data will include: (1) age at onset of regular transfusions, (2) years of chronic transfusion therapy, and (3) pre-transfusion Hb calculated as average of all assessments for each year.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 423
- 10-20 years of transfusion (defined as 0.2-0.6mg Fe/kg/day exposure with annual ferritin levels greater than 2500 in at least 60% of years of chronic transfusion);
- 0 to 9 years old at the initiation of chronic transfusions; no exchange transfusions in the previous 6 months
- iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months or ferritin level greater than 1500mg/dl.
- Patients with HbSC, HbS/β thalassemia
- Pacemaker (active or inactive) or other implanted magnetic devices, severe claustrophobia, or other contraindications to MRI; Unable to remove ferro-magnetic objects from the body in regions to be imaged (e.g., jewelry or piercing)
- Presence of any other condition which, in the opinion of the investigator, would make the patient unsuitable for enrollment;
- Any chronic inflammatory illness other than the SCD, THAL or DBA;
- Any acute illness within a 14 day period prior to blood sampling;
- Patients receiving intensive chelation in the 6 months prior to enrollment including deferoxamine 24 hours per day, 7 days per week or combination treatment with 2 chelators
- Pregnancy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identification of iron overloaded patients with Sickle Cell Disease and Thalassemia eligible for future study of iron deposition and biochemical mechanisms March 2010 - July 2013 Patients with similar duration of chronic transfusion and age at onset of chronic transfusion therapy will be identified from 10 participating centers. Detailed information on iron burden and transfusion, medical, and chelation histories will be obtained in order to establish a cohort of patients that could be available for a future powered study of extra-hepatic iron deposition and underlying biochemical mechanisms.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (8)
Children's Hospital & Research Center Oakland
🇺🇸Oakland, California, United States
Georgia Regents University
🇺🇸Augusta, Georgia, United States
Thomas Jefferson SCD Program
🇺🇸Philadelphia, Pennsylvania, United States
Adult Comprehensive Sickle Cell Center, Duke University Medical Center
🇺🇸Durham, North Carolina, United States
Children's Memorial Hospital
🇺🇸Chicago, Illinois, United States
UCL Cancer Institute
🇬🇧London, United Kingdom
Universitätsklinikum Hamburg-Eppendorf
🇩🇪Hamburg-Eppendorf, Germany
St. Jude Children's Research Hospital
🇺🇸Memphis, Tennessee, United States